PremiumCompany AnnouncementsNanobiotix Discloses Managerial Transactions in Compliance with EU Regulations Nanobiotix Updates Share Capital and Voting Rights as of April 2025 Nanobiotix to Present at H.C. Wainwright BioConnect Conference PremiumCompany AnnouncementsNanobiotix Reports Managerial Stock Transactions in April 2025 Nanobiotix Discloses Managerial Share Acquisitions in April 2025 Nanobiotix price target lowered to $8 from $12 at Guggenheim PremiumCompany AnnouncementsNanobiotix to Announce 2024 Financial Results and Host Conference Call Positive Clinical Data and Strategic Partnerships Drive Buy Rating for Nanobiotix Nanobiotix Reveals Promising Phase 1 Study Results for NBTXR3 in Advanced NSCLC